Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
We evaluate the suggestion that high-sensitivity C-reactive protein testing be used for risk assessment in the primary prevention of cardiovascular disease, using the criteria proposed by the Guide to Clinical Preventive Services developed by the US Preventive Services Task Force. We conclude that at present, none of the 3 major criteria—accuracy, reliability, and likelihood of beneficial intervention— are satisfied.
Kushner I, Sehgal AR. Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?. Arch Intern Med. 2002;162(8):867-869. doi:10.1001/archinte.162.8.867